Inside the research
Elanco Animal Health Incorporated
ELAN Research profile · latest available data
Price overview
$22.31
▼ -0.04 (-0.2%)
| 52w hi | $26.84 |
|---|---|
| 52w lo | $18.92 |
| Vol | 6.45M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.12
| Short | -0.36 |
|---|---|
| Medium | +0.03 |
| Long | +0.05 |
computed 2026-09-27
Key fundamentals
Elanco Animal Health Incorporated
Healthcare · Drug Manufacturers - Specialty & Generic
| Market cap | $11.14B |
|---|---|
| Enterprise value | $14.85B |
| Forward P/E | 17.36x |
| EV / EBITDA | 14.75x |
| P / S (ttm) | 2.22x |
| Profit margin | -4.0% |
| Return on equity | -3.0% |
| Revenue growth | +10.2% |
| Earnings growth | +440.5% |
| Debt / equity | 64.25 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.16 | |
| Sector | +0.08 | |
| Technical | -0.05 | |
| Earnings | +0.00 | |
| Sentiment | -0.33 |
macro × 1.00 · 2026-09-27
Business overview
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
Risk Metrics
| Beta vs SPX | 1.31 |
|---|---|
| Corr SPX | 0.45 |
| Annual vol | 47.1% |
| Annual ret | +33.8% |
| Sharpe | 0.72 |
| Max DD | -44.9% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $29.86 |
|---|---|
| High / Low | $32.00 / $24.00 |
| Median | $30.00 |
| Analysts | 14 |
| Strong Buy | 4 | |
|---|---|---|
| Buy | 11 | |
| Hold | 2 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-07 | JP Morgan | → Overweight |
| 2026-05-07 | Citigroup | → Buy |
| 2026-04-15 | Citigroup | → Buy |
| 2026-02-25 | Morgan Stanley | → Equal-Weight |
| 2026-02-25 | Keybanc | → Overweight |
| 2026-02-24 | Leerink Partners | → Outperform |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-05 | Earnings Release, Exhibits | read |
| 2026-05-27 | Shareholder Vote | read |
| 2026-05-06 | Earnings Release, Exhibits | read |
| 2026-02-24 | Earnings Release, Exhibits | read |
| 2026-01-12 | Reg FD Disclosure, Exhibits | read |
| 2025-12-09 | Restructuring, Reg FD Disclosure… | read |
| 2025-11-05 | Earnings Release, Exhibits | read |
| 2025-11-03 | Material Agreement, Material Obligation… | read |
| 2025-08-07 | Earnings Release, Exhibits | read |
| 2025-06-26 | Material Agreement, Material Obligation… | read |
| 2025-05-28 | Officer / Director Change, Reg FD Disclosure… | read |
| 2025-05-21 | Shareholder Vote | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Harrington Michael J | Director | Buy | 5.00K | $109.10K |
| 2026-08-07 | VanHimbergen Robert M | Officer, EVP and CFO | Buy | 4.20K | $96.93K |
| 2026-08-07 | Herendeen Paul | Director | Buy | 10.00K | $236.85K |
Flow & Concentration
| Insider 180d net | $442.88K |
|---|---|
| Insider buys / sells | 3 / 0 |
| Insider bias | Neutral |
| 13F holders | 0 |
| Top-5 share | 0.0% |
| HHI | 0 (—) |
SEC Filings
The Long Run
FY 2018–2025 · 8 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $4.42B | +6.3% | |
| Net income | $338.00M | +97.7% | |
| Cash from ops | $271.00M | -8.0% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $22.35 | $22.72 | $22.10 | $22.31 | 6.45M |
| Sep 24 | $22.59 | $22.63 | $21.75 | $22.35 | 7.64M |
| Sep 23 | $22.82 | $23.39 | $22.51 | $22.57 | 5.34M |
| Sep 22 | $22.53 | $23.18 | $22.51 | $22.93 | 5.61M |
| Sep 21 | $22.58 | $22.58 | $22.17 | $22.43 | 4.61M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →